Estrogen actions and in situ synthesis in human vascular smooth muscle cells and their correlation with atherosclerosis
- PMID: 15860269
- DOI: 10.1016/j.jsbmb.2004.12.024
Estrogen actions and in situ synthesis in human vascular smooth muscle cells and their correlation with atherosclerosis
Abstract
Various epidemiological studies have demonstrated a relatively low incidence of cardiovascular events in premenopausal women and its marked increment after menopause. In addition, estrogens have been postulated to exert direct anti-atherogenic effects via binding to estrogen receptors (ERs) in vascular smooth muscle cells (VSMCs). However, not all postmenopausal women develop atherosclerosis despite decreased levels of serum estrogen. Therefore, it is considered important to examine the status of estrogen metabolism in situ and of ER expression in the human cardiovascular system. Estrone sulfate (E1S) is a major circulating plasma estrogen that is converted into the biologically active estrogen, estrone (E1) by steroid sulfatase (STS). E1 is also sulfated and reverted into E1S by estrogen sulfotransferase (EST). These two enzymes have recently been shown to play important roles in the in situ estrogen actions of estrogen-dependent human tissues. STS and EST, however, have not been studied in detail in the human vascular system associated with atherosclerotic changes. Therefore, the relative abundance of STS- and EST-immunoreactive protein and mRNA expression in human aorta were evaluated using immunohistochemistry and reverse transcription followed by quantitative polymerase chain reaction in addition to enzyme activity. Furthermore, we evaluated the relative abundance of messenger RNA (mRNA) of both ER subtypes (ERalpha and ERbeta) in the human aorta using reverse transcription followed by quantitative polymerase chain reaction (RT-qPCR), as well as the immunoreactivity of both ERs in VSMCs of human atherosclerotic lesions. STS expression levels were found to be significantly higher in the VSMCs obtained from female aortas with mild atherosclerotic changes than in those with severe atherosclerotic changes and in male aortas regardless of atherosclerotic changes. EST expression levels in the VSMCs of these aortas, however, were significantly higher in female aortas with severe atherosclerotic changes and in male aortas than in female aortas with mild atherosclerotic changes. In addition, the number of ERalpha and/or ERbeta double positive cells in the neointima was higher in female aortas with a mild degree of atherosclerosis than in female aortas with severe atherosclerosis. They indicate that both abundance of these estrogen-metabolizing enzymes in female aorta and relative levels of ER in VSMCs of female neointima may be associated with the status of atherosclerotic changes.
Similar articles
-
Estrogen receptors in atherosclerotic human aorta: inhibition of human vascular smooth muscle cell proliferation by estrogens.Mol Cell Endocrinol. 2004 Apr 30;219(1-2):17-26. doi: 10.1016/j.mce.2004.02.013. Mol Cell Endocrinol. 2004. PMID: 15149723
-
Steroid sulfatase and estrogen sulfotransferase in the atherosclerotic human aorta.Am J Pathol. 2003 Oct;163(4):1329-39. doi: 10.1016/S0002-9440(10)63492-X. Am J Pathol. 2003. PMID: 14507642 Free PMC article.
-
Systemic distribution of steroid sulfatase and estrogen sulfotransferase in human adult and fetal tissues.J Clin Endocrinol Metab. 2002 Dec;87(12):5760-8. doi: 10.1210/jc.2002-020670. J Clin Endocrinol Metab. 2002. PMID: 12466383
-
New developments in intracrinology of human breast cancer: estrogen sulfatase and sulfotransferase.Ann N Y Acad Sci. 2009 Feb;1155:76-9. doi: 10.1111/j.1749-6632.2008.03683.x. Ann N Y Acad Sci. 2009. PMID: 19250194 Review.
-
Steroid sulfatase and estrogen sulfotransferase in human carcinomas.Mol Cell Endocrinol. 2011 Jul 4;340(2):148-53. doi: 10.1016/j.mce.2010.11.001. Epub 2010 Nov 10. Mol Cell Endocrinol. 2011. PMID: 21073915 Review.
Cited by
-
Altered serum metabolome associated with vascular calcification developed from CKD and the critical pathways.Front Cardiovasc Med. 2023 Apr 11;10:1114528. doi: 10.3389/fcvm.2023.1114528. eCollection 2023. Front Cardiovasc Med. 2023. PMID: 37113701 Free PMC article.
-
Gender differences in the cardiovascular effect of sex hormones.Nat Rev Cardiol. 2009 Aug;6(8):532-42. doi: 10.1038/nrcardio.2009.105. Epub 2009 Jun 30. Nat Rev Cardiol. 2009. PMID: 19564884 Review.
-
Does rapid metabolism ensure negligible risk from bisphenol A?Environ Health Perspect. 2009 Nov;117(11):1639-43. doi: 10.1289/ehp.0901010. Epub 2009 Jul 14. Environ Health Perspect. 2009. PMID: 20049111 Free PMC article.
-
Methotrexate associates with ischemic cardiovascular risk reduction in males but not females: a transatlantic cardiovascular consortium for people with rheumatoid arthritis observational study.Rheumatol Int. 2025 Apr 18;45(5):106. doi: 10.1007/s00296-025-05838-y. Rheumatol Int. 2025. PMID: 40249410
-
Sex-Specific Impact of 17β-Estradiol and Testosterone Levels on Inflammation and Injury in Acute Myocardial Infarction-Preliminary Results.Biomedicines. 2025 Jun 13;13(6):1466. doi: 10.3390/biomedicines13061466. Biomedicines. 2025. PMID: 40564184 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Research Materials